11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection
Key Takeaways
Calcineurin inhibitors cause hyperkalemia, hypomagnesemia, hypertension and hyperglycemia; tacrolimus is the more diabetogenic and cyclosporine the more hyperlipidemic of the two.
mTOR inhibitors (sirolimus, everolimus) commonly cause hyperlipidemia, impaired wound healing and proteinuria.
KDOQI 2020 recommends limiting sodium to under 2.3 g/day after transplant (1C) and suggests a Mediterranean diet to improve lipid profiles (2C).
KDOQI 2020 suggests not routinely prescribing long-chain omega-3 fatty acids to reduce rejection or improve graft survival (2D).
Commonly used long-term targets for a stable graft are about 0.8–1.0 g protein/kg and energy matched to a healthy weight, with protein lowered as graft function declines.
The shift from dialysis restrictions to chronic-disease prevention
Once a graft is stable, often within 2–3 months, most dialysis-era restrictions can be lifted. Serum potassium and phosphorus are managed to their actual values rather than restricted by habit, and fluid is usually generous. The leading long-term threats to a recipient are cardiovascular disease, post-transplant diabetes, obesity, bone disease, infection, cancer and chronic graft injury. Nutrition care therefore shifts from restriction to prevention.
KDOQI 2020 extends several statements to transplant recipients (written as "posttransplantation"):
- Energy: 25–35 kcal/kg/day for metabolically stable adults (3.1.1, OPINION for transplant).
- Sodium: less than 100 mmol/day (<2.3 g/day) to reduce blood pressure and improve volume control (6.5.1, grade 1C).
- Potassium: adjust intake to keep serum potassium normal (6.4.1).
- Mediterranean diet: may improve lipid profiles (3.3.1, grade 2C).
- Omega-3 fatty acids: do not prescribe routinely to reduce rejection or improve graft survival (4.3.7, grade 2D).
- Vitamin D: correct 25(OH)D deficiency with cholecalciferol or ergocalciferol (5.3.1).
- Monitoring: check body weight and BMI at least every 3 months after transplant (1.1.5). Both underweight and overweight or obesity predict higher mortality in recipients (1.1.10).
Long-term protein targets in commonly used references are about 0.8–1.0 g/kg/day for a well-functioning graft. Some references suggest the lower end without diabetes. If the graft fails and GFR falls, protein advice follows the CKD stage.
Immunosuppressants and their nutrition effects
| Drug class (examples) | Main nutrition-related effects | Dietitian response |
|---|---|---|
| Calcineurin inhibitors: tacrolimus, cyclosporine | Hyperkalemia, hypomagnesemia, hypertension, hyperglycemia (tacrolimus more so), hyperlipidemia (cyclosporine more so), tremor; cyclosporine causes gingival overgrowth | Monitor potassium, magnesium, glucose and lipids; avoid grapefruit, pomelo and Seville orange; take at consistent times relative to meals |
| Antimetabolites: mycophenolate, azathioprine | Nausea, diarrhea and abdominal pain (mycophenolate); marrow suppression | Small frequent meals; replace fluid and electrolyte losses; report persistent diarrhea |
| mTOR inhibitors: sirolimus, everolimus | Hyperlipidemia (especially triglycerides), impaired wound healing, mouth ulcers, proteinuria, edema | Lipid-lowering diet; protein and wound nutrition around surgery |
| Corticosteroids: prednisone | Hyperglycemia, increased appetite, weight gain, sodium retention, muscle wasting, bone loss | Carbohydrate and portion counseling; calcium and vitamin D adequacy; resistance exercise |
| Costimulation blocker: belatacept | Fewer metabolic effects than calcineurin inhibitors | Standard healthy-diet counseling |
| Infection prophylaxis: trimethoprim-sulfamethoxazole | Raises serum potassium and creatinine | Consider before restricting dietary potassium |
Post-transplant diabetes mellitus (PTDM)
PTDM develops in a meaningful share of recipients within the first year. Risk factors include older age, obesity, family history, hepatitis C, tacrolimus and corticosteroids. Key points:
- Diagnose PTDM once the patient is stable on maintenance immunosuppression, not in the first weeks of stress hyperglycemia.
- An oral glucose tolerance test detects more cases than fasting glucose. HbA1c used alone can miss PTDM early after transplant, because anemia, blood loss and transfusion distort it.
- Treatment starts with lifestyle change (weight management, carbohydrate quality, physical activity) and adds medications chosen by the team.
Weight gain and obesity
Appetite improves once uremia resolves and corticosteroids stimulate eating, so weight gain in the first year is common. Rising BMI raises the risk of PTDM, hypertension, dyslipidemia and cardiovascular events. Start preventive counseling before the weight arrives: set a goal weight, plan portions, limit sugary drinks and schedule regular weigh-ins.
Cardiovascular risk: blood pressure and lipids
- Blood pressure: sodium under 2.3 g/day (KDOQI) combined with a DASH or Mediterranean pattern, weight control and limited alcohol.
- Lipids: calcineurin and mTOR inhibitors and steroids worsen lipids. KDIGO's 2013 lipid guideline suggests statin treatment for adult kidney transplant recipients. Some statins interact with cyclosporine, so the team chooses the agent and dose. The dietitian supports a pattern low in saturated and trans fat, with more fiber, fish and plant proteins.
Bone and mineral disease after transplant
Pre-existing renal osteodystrophy, steroids and persistent hyperparathyroidism cause early bone loss.
- Tertiary hyperparathyroidism can cause hypercalcemia with low phosphorus after transplant.
- Ensure adequate calcium intake from food and correct vitamin D deficiency.
- Encourage weight-bearing and resistance exercise.
- Medication decisions (calcitriol, antiresorptives, calcimimetics or parathyroidectomy) belong to the team. They follow KDIGO's CKD-MBD guidance on bone-density testing and treatment in transplant recipients.
Anemia, magnesium and potassium in the long term
Post-transplant anemia is common and often reflects iron deficiency, drug effects or declining graft function. KDIGO's 2026 anemia guideline includes kidney transplant recipients among people not on dialysis when choosing the hemoglobin at which to start an ESA. Persistent hypomagnesemia from calcineurin inhibitors often needs ongoing magnesium supplements and magnesium-rich foods (nuts, legumes, whole grains) as potassium allows. Unexplained hyperkalemia should trigger a review of calcineurin-inhibitor levels, trimethoprim-sulfamethoxazole, RAAS blockers and metabolic acidosis before a strict potassium diet is imposed.
When the graft declines
Transplant recipients are staged by eGFR and albuminuria like anyone with CKD. As function falls, nutrition care returns to CKD principles: attention to sodium, potassium, phosphorus and acid–base balance, and protein adjusted to stage and metabolic stability. If dialysis is needed again, dialysis protein targets (1.0–1.2 g/kg) apply. The patient may also be evaluated for a second transplant, so nutrition status matters again.
Long-term follow-up checklist for the dietitian
- Weight, BMI and waist trend at least every 3 months (KDOQI 1.1.5).
- Glucose and HbA1c, lipids, blood pressure, potassium, magnesium, phosphorus, calcium and 25(OH)D.
- Diet quality: sodium, saturated fat, sugar-sweetened beverages, fiber and alcohol.
- Food safety, grapefruit-family avoidance and supplement review at every visit.
- Physical activity and bone health.
Eighteen months after transplant, a recipient on tacrolimus, mycophenolate and low-dose prednisone has gained 11 kg. Fasting glucose is 138 mg/dL on two occasions, LDL cholesterol is 162 mg/dL, and blood pressure is 146/90 mmHg. Which nutrition recommendation best matches KDOQI 2020 statements for transplant recipients?
A very-low-protein diet of 0.3 g/kg with ketoacid analogues to protect the graft.
High-dose fish oil to reduce rejection risk, with no other dietary change.
Unrestricted sodium because the graft now excretes sodium normally.
A Mediterranean-style eating pattern with sodium under 2.3 g/day, calorie control toward a healthy weight, and team evaluation for post-transplant diabetes.
A kidney transplant recipient has serum potassium of 5.8 mEq/L and magnesium of 1.2 mg/dL. The patient eats a moderate-potassium diet. Which medication is most likely contributing to both abnormalities?
Tacrolimus
Mycophenolate mofetil
Belatacept
Low-dose aspirin
Six years after transplant, a patient's graft function has declined to an eGFR of 22 mL/min/1.73 m² with rising serum phosphorus. How should nutrition care change?
Keep the unrestricted post-transplant diet, because transplant recipients are not staged as CKD.
Return to CKD-based care matched to the stage: individualized protein, phosphorus attention (including additive avoidance), sodium limits and potassium management according to labs.
Start a dialysis-level protein target of 1.2 g/kg immediately to prevent wasting.
Stop all monitoring until dialysis starts.
Sections you finish are checked off in the contents.